Dynamics of macrophage trogocytosis of rituximab-coated B cells

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Pham, Theodore ^a,b,c   Mero, Patricia ^a,b   Booth, James W ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Institute of Clinical Evaluative Sciences   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ARSENOSOBENZENE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RITUXIMAB; CD20 ANTIGEN; MONOCLONAL ANTIBODY; OPSONIN;

ACTIN POLYMERIZATION; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL ADHESION; CELL MEMBRANE; CELL SHAPE; CELL STRAIN; CELL STRAIN RAW264.7; CELL STRUCTURE; CONTROLLED STUDY; DYNAMICS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTERNALIZATION; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; OPSONIZATION; PROTEIN DEFECT; RAMOS CELL; TARGET CELL; TROGOCYTOSIS; ANIMAL; CELL LINE; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; KINETICS; MACROPHAGE; METABOLISM; METHODOLOGY; PHYSIOLOGY;

UROPODA;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; CELL LINE; CELL SHAPE; FLOW CYTOMETRY; KINETICS; MACROPHAGES; MICE; OPSONIN PROTEINS;

EID: 79251575310     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014498     Document Type: Article

References (33)

1. Greenberg S, Grinstein S (2002) Phagocytosis and innate immunity. Curr Opin Immunol 14: 136-145. 10.1016/S0952-7915(01)00309-0.
2. Booth JW, Kim MK, Jankowski A, Schreiber AD, Grinstein S (2002) Contrasting requirements for ubiquitylation during Fc receptor-mediated endocytosis and phagocytosis. EMBO J 21: 251-258. 10.1093/emboj/21.3.251.
3. Mero P, Zhang CY, Huang ZY, Kim MK, Schreiber AD, et al. (2006) Phosphorylation-independent Ubiquitylation and Endocytosis of Fc{gamma} RIIA. J Biol Chem 281: 33242-33249. 10.1074/jbc.M605372200.
4. Tse SM, Furuya W, Gold E, Schreiber AD, Sandvig K, et al. (2003) Differential role of actin, clathrin, and dynamin in Fc gamma receptor-mediated endocytosis and phagocytosis. J Biol Chem 278: 3331-3338. 10.1074/jbc.M207966200.
5. Joly E, Hudrisier D (2003) What is trogocytosis and what is its purpose? Nat Immunol 4: 815. 10.1038/ni0903-815.
6. Hudrisier D, Riond J, Mazarguil H, Gairin JE, Joly E (2001) Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signalingdependent manner. J Immunol 166: 3645-3649.
7. Ford McIntyre MS, Young KJ, Gao J, Joe B, Zhang L (2008) Cutting edge: in vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigen-specific suppression. J Immunol 181: 2271-2275.
8. Huang JF, Yang Y, Sepulveda H, Shi W, Hwang I, et al. (1999) TCR-Mediated internalization of peptide-MHC complexes acquired by T cells. Science 286: 952-954. 10.1126/science.286.5441.952.
9. Batista FD, Iber D, Neuberger MS (2001) B cells acquire antigen from target cells after synapse formation. Nature 411: 489-494. 10.1038/35078099.
10. McCann FE, Eissmann P, Onfelt B, Leung R, Davis DM (2007) The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences. J Immunol 178: 3418-3426.
11. Griffin FM, Jr., Griffin JA, Silverstein SC (1976) Studies on the mechanism of phagocytosis. II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes. J Exp Med 144: 788-809.
12. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP (2006) The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 176: 2600-2609.
13. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP (2008) Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 181: 8120-8132.
14. Daubeuf S, Lindorfer MA, Taylor RP, Joly E, Hudrisier D (2010) The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell. J Immunol 184: 1897-1908. 10.4049/jimmunol.0901570.
15. Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, et al. (2006) Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 177: 7435-7443.
16. Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104: 2635-2642. 10.1182/ blood-2004-03-1110.
17. Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2: 52-62. 10.1038/ nrd984.
18. Aucher A, Magdeleine E, Joly E, Hudrisier D (2008) Capture of plasma membrane fragments from target cells by trogocytosis requires signaling in T cells but not in B cells. Blood 111: 5621-5628. 10.1182/blood-2008-01-134155.
19. Swanson JA, Hoppe AD (2004) The coordination of signaling during Fc receptormediated phagocytosis. J Leukoc Biol 76: 1093-1103. 10.1189/jlb.0804439.
20. Marshall JG, Booth JW, Stambolic V, Mak T, Balla T, et al. (2001) Restricted accumulation of phosphatidylinositol 3-kinase products in a plasmalemmal subdomain during Fc gamma receptor-mediated phagocytosis. J Cell Biol 153: 1369-1380. 10.1083/jcb.153.7.1369.
21. Cox D, Tseng CC, Bjekic G, Greenberg S (1999) A requirement for phosphatidylinositol 3-kinase in pseudopod extension. J Biol Chem 274: 1240-1247. 10.1074/jbc.274.3.1240.
22. Collins RF, Touret N, Kuwata H, Tandon NN, Grinstein S, et al. (2009) Uptake of oxidized low density lipoprotein by CD36 occurs by an actin-dependent pathway distinct from macropinocytosis. J Biol Chem 284: 30288-30297. 10.1074/jbc.M109.045104.
23. Petrie RJ, Deans JP (2002) Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J Immunol 2002 Sep 15;169(6): 2886-91 169: 2886-2891.
24. Perosa F, Favoino E, Vicenti C, Merchionne F, Dammacco F (2007) Identification of an Antigenic and Immunogenic Motif Expressed by Two 7- Mer Rituximab-Specific Cyclic Peptide Mimotopes: Implication for Peptide-Based Active Immunotherapy. J Immunol 179: 7967-7974.
25. Griffin FM, Jr., Griffin JA, Leider JE, Silverstein SC (1975) Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane. J Exp Med 142: 1263-1282.
26. Champion JA, Mitragotri S (2006) Role of target geometry in phagocytosis. Proceedings of the National Academy of Sciences of the United States of America 103: 4930-4934. 10.1073/pnas.0600997103.
27. Gratton SEA, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, et al. (2008) The effect of particle design on cellular internalization pathways. Proceedings of the National Academy of Sciences 105: 11613-11618. 10.1073/pnas.0801763105.
28. Daubeuf S, Aucher A, Bordier C, Salles A, Serre L, et al. (2010) Preferential transfer of certain plasma membrane proteins onto T and B cells by trogocytosis. PLoS One 5: e8716. 10.1371/journal.pone.0008716.
29. Hudrisier D, Clemenceau B, Balor S, Daubeuf S, Magdeleine E, et al. (2009) Ligand binding but undetected functional response of FcR after their capture by T cells via trogocytosis. J Immunol 183: 6102-6113. 10.4049/jimmunol.0900821.
30. Ho Wang Yin KY, Alegre E, Daouya M, Favier B, Carosella ED, et al. (2010) Different functional outcomes of intercellular membrane transfers to monocytes and T cells. Cell Mol Life Sci 67: 1133-1145. 10.1007/s00018-009-0239-4.
31. Beum PV, Lindorfer MA, Taylor RP (2008) Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab- Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving. J Immunol 181: 2916-2924.
32. Taylor RP, Lindorfer MA (2007) Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 3: 86-95. 10.1038/ncprheum0424.
33. Zhang QJ, Li XL, Wang D, Huang XC, Mathis JM, et al. (2008) Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses. PLoS One 3: e3097. 10.1371/journal.pone.0003097.